DETERMINATION OF PINAVERIUM BROMIDE IN PHARMACEUTICAL DOSAGE FORMS BY A VALIDATED STABILITY-INDICATING LC METHOD by Sangoi, Maximiliano da Silva et al.
 Drug Analytical Research 





Determination of Pinaverium Bromide in pharmaceutical dosage forms by a 
validated Stability-Indicating LC Method 
 
Maximiliano da Silva Sangoi*, Anna Karolina Mouzer da Silva Machado, Lorena Coimbra Florindo, Brenda Rocha 
Gonçalves, Vítor Todeschini 
 
Laboratory of Pharmaceutical Analysis, Faculty of Pharmacy, Federal University of Rio de Janeiro, 27930-560 Macaé-
RJ, Brazil 
*
 Corresponding author: e-mail: maxsilvasangoi@yahoo.com.br 
 
A reversed-phase liquid chromatography (LC) method was validated for the determination of pinaverium bromide (PB) 
in pharmaceutical dosage forms. The LC method was carried out on a reversed-phase monolithic C18 column (100 x 4.6 
mm i.d.), maintained at 45 ºC. The mobile phase consisted of acetonitrile and a solution of triethylamine 0.3% pH 5.0 
(50:50; v/v), run at a flow rate of 2.0 mL/min, with photodiode array detector set at 213 nm. The chromatographic 
separation was obtained with PB retention time of 3.4 min, and it is linear in the range of 5-100 μg/mL (R2 = 0.9991). 
The limits of detection and quantitation are 1.41 and 4.70 μg/mL, respectively. The specificity and stability-indicating 
capability of the method were proven through degradation studies, which also showed that there is no interference of the 
formulation excipients, showing that peak is free from any co-eluting peak. The method showed adequate precision, with 
a relative standard deviation values lower than 1.38%. Excellent values of accuracy were obtained, with a mean value of 
100.68%. Experimental design was used during validation to calculate and prove method robustness. The proposed LC 
method is applied for the analysis of the PB pharmaceutical dosage forms, contributing to improve the quality control 
and to assure the therapeutic efficacy. 
 




Irritable bowel syndrome (IBS) is the most 
commonly diagnosed functional gastrointestinal 
disorder characterized by chronic abdominal pain and 
changed bowel habits in the absence of an overtly 
identifiable cause (1). The prevalence of IBS in Europe 
and North America is estimated to be 10-15% and up 
to 33% in the worldwide population (2). IBS has 
gained significant interest in healthcare due to its high 
occurrence, complex pathophysiology, difficult 
diagnosis due to a wide range of non-specific 
symptoms, and varied and challenging treatment 
options (3).  
Antispasmodics improve IBS symptoms by directly 
relaxing the colonic smooth muscle cells or 
antagonizing the excitatory neuromuscular 
neurotransmission. Antispasmodics remain one of the 
most commonly prescribed groups of medications for 
the treatment of IBS (4). Pinaverium bromide (PB; 
Figure 1), an antispasmodic, is a commonly drug 
administered worldwide (5). 
Liquid chromatography (LC) is a versatile 
separation technique with wide range of applications, 
usually the analytical method of choice for 
pharmaceutical quality control and impurity profile 
(6,7). However, there are still ample opportunities for 
improvements based on specificity and sensitivity, 
enhancing robustness or improving cost effectiveness, 
such as chemometry and column technology.  
 
 
Figure 1. Chemical structure of bromide pinaverium. 
 
Chemometric approaches have been increasingly 
viewed as precious complements to chromatographic 
practices, since a large number of variables can be 
simultaneously controlled to achieve the desired 
separations. Moreover, applications of suitable 
statistical analysis may efficiently identify and 
optimize the significant factors to accomplish 
competent results through limited experimental trials 
with lower reagent consumption and less laboratory 
work (8,9). 
There is a continuous development of new column 
materials, which may be used in the separation of 
impurities given that this will offer an advantage over 
legacy materials (10). An interesting alternative to 
particulate-based LC columns are monolithic columns. 





Silica monoliths are ideal for small molecule 
applications with high efficiencies, higher flow rates 
and lower operating pressures, successfully applied to 
impurity profiling and quality control (11-13). 
For the analysis of PB in tablets, two 
spectrophotometric methods have been developed by 
our research group (14). However there is no 
publication concerning LC method in the current 
literature. Therefore, the aim of the present article was 
to develop a selective, simple, rapid and validated 
stability-indicating LC method on a monolithic 
reversed-phase column to perform forced 
decomposition studies, contributing to improve the 
quality control and ensuring therapeutic efficacy.  
 
Experimental 
Chemicals and reagents 
The PB reference substance (purity 100.3%) was 
acquired from the Pharmacopeia Comércio e 
Importação Ltda (Barueri, SP, Brazil). Dicetel® tablets 
(Abbott Laboratories Ltda, SP, Brazil) containing 50 
mg and 100 mg of PB were obtained from commercial 
source and used within their shelf life period. The 
excipients contained in the dosage form were all of 
pharmaceutical grades and acquired from different 
suppliers for placebo preparation. LC-grade 
triethylamine, phosphoric acid 85% and acetonitrile 
were obtained from Tedia Company Inc (Fairfield, OH, 
USA). Ultrapure water (Milli-Q® Direct Water 
Purification System, Merck Millipore Corporation, 




The stock solution of the drug was prepared by 
accurately weighing 20 mg of PB reference substance 
and diluting to volume with acetonitrile to obtain the 
concentration of 1.0 mg/mL. The stock solution was 
stored at 2-8 °C, protected from light and daily diluted 
to an appropriate concentration. 
To prepare the tablet solutions, tablets containing 
50 mg or 100 mg of PB were accurately weighed and 
crushed to a fine powder. A quantity equivalent of 10 
mg PB was transferred into individual 100 mL 
volumetric flasks. After adding 70 mL of 
acetonitrile/water (1:1; v/v), the flasks were vortex 
mixed for 3 minutes, followed by 10 minutes in 
ultrasonic bath. The samples were made up to volume 
with the same diluent. Working sample solutions were 
prepared prior to the analysis by diluting the stock 
solutions to the appropriate concentrations in mobile-
phase. Both sample and reference solutions were then 
filtered through a 0.45μm membrane filter (Millipore) 
prior to the injection. 
 
Apparatus and analytical conditions 
The LC method was performed on a Prominence 
HPLC system (Shimadzu, Kyoto, Japan) equipped with 
a CBM-20A system controller, an LC-20AD pump, a 
DGU-20A degasser, a SIL-20A autosampler and an 
SPD-M20A photodiode array (PDA) detector. The 
peak areas were integrated automatically using an 
LCsolution software. The experiments were performed 
on a reversed phase Onyx® C18 monolithic column 
(100 x 4.6 mm i.d., Phenomenex, Torrance, CA, USA). 
The LC system was operated isocratically at controlled 
temperature (45 °C) using as mobile phase acetonitrile 
and a solution of triethylamine 0.3% pH 5.0 (adjusted 
with phosphoric acid 8.5%) (50:50; v/v), run at a flow 
rate of 2.0 mL/min, and using PDA detection at 213 
nm. The injection volume was 10 μL. 
 
Validation procedure 
The objective of validation of an analytical 
procedure is to demonstrate that it is suitable for its 
intended purpose. The method was validated for 
specificity, linearity and range, precision, accuracy, 
detection limit, quantitation limit and robustness 
(15,16). 
 
Specificity and forced degradation studies 
The specificity of an analytical method may be 
defined as the ability to determine the analyte in the 
presence of additional components such as impurities, 
degradation products, and matrix compounds (15). The 
interference of the excipients of the pharmaceutical 
formulation was determined by the injection of a 
sample containing only placebo (in-house mixture of 
all the tablet excipients) reference solution, and the 
commercial pharmaceutical preparation at the 
concentrations of 50 μg/mL of PB. 
The stability-indicating capability of the method 
was determined by subjecting the reference solution 
(200 μg/mL) to accelerated degradation conditions 
such as: light exposure, acidic, basic and oxidative 
media to evaluate the interference in the analyte 
quantification. Hydrochloric acid was added to the 
sample solution to achieve the final concentration of 
0.2M to verify the acid hydrolysis. The addition of 
sodium hydroxide to the sample solution to obtain a 
concentration of 1M was performed for the basic 
hydrolysis evaluation. Both solutions were neutralized 
with base and acid, respectively, after a pre-determined 
period of time. The oxidative degradation was induced 
by storing the sample solution in 15% hydrogen 
peroxide. All these solutions were kept in ambient 
temperature (25 °C) and protected from light to prevent 
the interference of photolytic degradation. 
Photodegradation was induced by exposing the sample 
in the photostability chambers to near UV-A (365 nm) 
and UV-C (254 nm) light for 4 h and 30 min, 
respectively. After subjecting the samples to stress 
studies, they were withdrawn at suitable time intervals 
and diluted with the mobile phase to theoretical PB 
final concentrations of 50 μg/mL before LC injection. 
Then the specificity and the stability-indicating 
capability of the method were established by 
determining the PB peak purity using PDA detector. 
 
Linearity and range 





The linearity was determined by constructing three 
independent analytical curves, each one with six 
concentrations of reference solution, in the range of 5-
100 μg/mL (5; 10; 25; 50; 75; 100 μg/mL) prepared in 
mobile-phase. Before injection of the solutions, the 
column was equilibrated for at least 20 min with the 
mobile phase flowing through the system. The peak 
areas of the compound were plotted against the 
respective concentration of PB to obtain the analytical 
curve.  
 
Precision and accuracy 
The precision of the method was determined by 
repeatability and intermediate precision. Repeatability 
was verified by six independent sample preparations of 
the same concentration of PB, on the same day, under 
the same experimental conditions. The intermediate 
precision was studied by comparing the results 
obtained on three different days.  The accuracy was 
evaluated by applying the proposed method to the 
analysis of an in-house mixture of the excipients with 
known amounts of the drug, to obtain solutions at 
concentrations of 40, 50 and 60 μg/mL, equivalent to 
80, 100 and 120% of the nominal analytical 
concentration, respectively. The accuracy was 
calculated as the percentage of the drug recovered from 
the formulation matrix. 
 
Detection/quantitation limits 
Detection/quantitation limits parameters are not a 
requirement for drug assay, however, it is always 
useful to demonstrate the sensitivity of the method and 
that the analysis is conducted in a region that is above 
of the quantitation limit value. The 
detection/quantitation limits were calculated from the 
analytical curve. Limits were calculated from the slope 
and the standard deviation of the intercept of three 
calibration curves, determined by a linear regression 




In order to study the simultaneous variation of the 
factors in the considered responses, a multivariate 
approach using design of experiments (DoE) is 
recommended in robustness testing (15,16). The DoE 
selected was a two-level fractional factorial design (24-
1) performed to examine the effects of four factors 
(triethylamine solution pH, triethylamine 
concentration, percentage of acetonitrile, and column 
temperature) at two levels in 9 experiments. The low 
and high levels were deliberately selected on the basis 
of small changes in method parameters, providing an 
indication of its reliability during normal usage. The 
obtained responses – drug assay (%) and retention time 
(min) – were processed by Minitab 17 statistical 
software to evaluate the significance of the effects, 
which were represented by Pareto charts.   
Solution stability 
The stability of sample solutions in mobile phase 
was assessed after the storage of the samples for 48 h at 
2-8 ºC, and also placed into the autosampler, at room 
temperature for 24 h.  
 
Sample analysis 
For PB quantitation in the tablet formulations, the 
respective stock sample solutions were diluted to an 
appropriate concentration (50 µg/mL) with mobile-
phase, filtered, injected in triplicate and the percentage 
recoveries of the drug calculated against the reference 
substance. 
 
Results and Discussion 
Method optimization 
The effect of the composition of the column and 
mobile-phase on the retention time of PB and on its 
chromatographic parameters was initially investigated. 
The chromatographic conditions were chosen after 
testing different mobile-phases with distinct 
proportions of organic solvent (acetonitrile or 
methanol) and water, with and without triethylamine, 
in different pH values of the aqueous phases. 
Phosphate buffers were also tested. The adequacy of 
the mobile-phase was decided on basis of selectivity 
and sensitivity of the assay, stability studies and the 
separation between the drug and degraded products 
formed during forced degradation studies. Moreover, 
the best chromatographic separation of degradation 
products and PB was achieved by using the monolithic 
column. The use of triethylamine solution (0.3%; pH 
5.0) in combination with acetonitrile (50:50; v/v), at 45 
°C, resulted in a relatively short retention time of 3.4 
min, and a simple mobile phase (without buffer 
addition), as shown in the typical chromatogram 
(Figure 2a). The optimized conditions of the LC 
method were validated for the analysis of PB in 
pharmaceuticals formulations, in order to provide 
capability and application for the quality control. 
 
Method Validation 
Specificity and forced degradation studies 
A stability-indicating method is defined as an 
analytical method that accurately quantifies the active 
ingredients without interference from degradation 
products, process impurities, excipients, or other 
potential impurities (15). Forced degradation studies 
should be the first step in method development. The 
presence of degradants and impurities in 
pharmaceutical formulations can result in changes in 
their chemical, pharmacological and toxicological 
properties affecting their efficacy and safety. 
Therefore, the adoption of stability-indicating methods 
is always required to control the quality of 
pharmaceuticals during and after the production. This 
greatly contributes to the possibility of improving drug 
safety (17,18). 





During the forced degradations PB remained stable 
under basic and acidic hydrolysis, oxidative and UV-A 
photolytic conditions. However, the exposure of drug 
to UV-C (254 nm) light for 90 min resulted in full 
degradation of the drug. Exposing the PB for 20 min, 
around 64% degradation was seen and five additional 
peaks were detected at 0.79, 0.90, 1.05, 1.48 and 2.32 
min. Moreover, no interference from formulation 
excipients was found, showing that the drug peak were 
free from any co-eluting substance, thus demonstrating 
that the proposed method is specific for the analysis of 
PB. The chromatograms of forced degradation studies 





Figure 2. LC chromatograms of pinaverium bromide (PB) at 
50 µg/mL. (a) PB reference substance solution; (b) PB tablet 
solution; (c) PB photolytic degradation in the photostability 
chambers to near UV-C (254 nm) (t = 20 min). 
Chromatographic conditions: Phenomenex Onyx C18 
monolithic column (100 mm x 4.6 mm i.d.), 45 °C; mobile 
phase: acetonitrile-triethylamine solution 0.3% (pH 5.0) 
(50:50; v/v); flow rate: 2.0 mL/min; injection: 10 µL. 
 
Linearity 
The analytical curves constructed for PB were 
found to be linear in the 5-100 µg/mL range. This 
range corresponded to 10-200% of the intended test 
concentration of 50 µg/mL for the pharmaceutical 
quality control of PB and the drug in its formulation. 
The value of the determination coefficient calculated 
(R2 = 0.9991, y = 3305x - 2098), where x is 
concentration and y is the peak absolute area, indicated 
the linearity of the analytical curve for the method.  
 
Precision 
Precision was determined by studying the intra-day 
and inter-day precision. The experimental values 
obtained for the determination of PB in samples are 
presented in Table 1. The variability of the results was 
low with RSD values less than 1.38% to intra-day 
precision, and the value of inter-day precision was 
1.26% in tablets. RSD values found for the analytical 
method were within the acceptable range indicating 
that this method has excellent repeatability and 
intermediate precision. 
 
Table 1. Intra-day and inter-day precision data of LC method 
for pinaverium bromide in tablet dosage form. 
 
Sample Day 1 Day 2 Day 3 
1 101.13% 99.91% 98.59% 
2 100.77% 100.42% 100.60% 
3 98.17% 98.95% 102.23% 
4 101.90% 98.07% 100.29% 
5 100.01% 102.03% 99.62% 
6 101.41% 100.57% 99.57% 
Intra-day 
precisiona (n = 6) 
100.57% ± 
1.33% 





precisiona (n = 18) 100.24% ± 1.26% 
a Mean ± RSD (Relative standard deviation) 
 
Accuracy 
The accuracy was assessed from three replicate 
determinations of three different solutions containing 
40, 50 and 60 μg/mL. The absolute means obtained for 
PB are shown in Table 2 with a mean value of 
100.68% and RSDs lower than 1.58%, demonstrating 
that the method is accurate within the desired range.   
 
Table 2. Accuracy data for proposed LC method. 
 
a Mean of three replicates. 











40 (80%) 40.77 0.78 101.92 
50 (100%) 50.19 0.45 100.37 
60 (120%) 59.84 1.58 99.74 






Detection/quantitation limits were obtained by 
using the mean of the slope, 3302.86 ± 140.54 and the 
standard deviation of the intercept of the independent 
curves, determined by a linear regression line as -
2495.13. The detection limit and quantitation limit 
calculated were 1.41 and 4.70 μg/mL, respectively. 
 
Robustness 
The susceptibility of the developed analytical 
method to changes was tested in order to evaluate the 
robustness. For this purpose a two-level fractional 
factorial design was employed. The experimental plan 
and the corresponding responses are summarized in 
Table 3. 
 
Table 3. Selected two-level fractional factorial design for the 
robustness testing of pinaverium bromide 











1 4.8 52 0.2 47 101.17 3.19 
2 5.2 52 0.4 47 101.13 2.87 
3 4.8 52 0.4 43 100.86 2.79 
4 5.2 48 0.2 47 101.12 4.56 
5e 5.0 50 0.3 45 101.07 3.43 
6 5.2 52 0.2 43 100.79 4.01 
7 5.2 48 0.4 43 101.10 3.48 
8 4.8 48 0.4 47 102.18 3.67 
9 4.8 48 0.2 43 101.49 4.46 
a
 Triethylamine pH 
b
 Acetonitrile (%) 
c
 Triethylamine concentration (%) 
d
 Column temperature (°C) 
e
 Optimal conditions 
 
 
The significance of the effects was evaluated by a 
Pareto chart (Figure 3) that consists of bars with a 
length proportional to the absolute value of the 
estimated effect, divided by the pseudo standard error 
defined by Lenth (Lenth’s PSE) (19). The codes A, B, 
and C correspond to each of the parameters. The 
combination of two or three codes indicates the 
interaction effect between the variables. The bars were 
displayed based in the size of the effect, with the 
largest effect on the top. The chart includes a vertical 
line at the critical t-value (α = 0.05). Effects in which 
the bars are smaller than the critical t-value were not 
considered significant and did not affect the response 
variables. 
 
   
 
Figure 3. Pareto charts representing the effects of the 
variables and their interactions on the PB (a) assay and (b) 




The stability of the both reference and sample 
solutions was studied and the data obtained showed the 
stability during 24 h in the autosampler and during 48 h 
when maintained at 2-8 °C. The retention time and 
peak area of PB remained almost unchanged and non-
significant degradation was observed within the 




Acceptable results of application of the proposed 
method in tablet dosage forms (Table 2) were obtained, 
demonstrating the quality of the pharmaceutical 
samples and the applicability of the validated method 
for quality control analysis of PB. It should be 
considered that excipients did not interfere in the 




The high-throughput assay is an extremely 
important advantage of LC methods using monolithic 
columns, especially during new product development 
and validation of manufacturing processes. The results 
of the validation studies showed that the stability 
indicating LC method is specific, accurate, robust, and 





possesses significant linearity and precision, without 
any interference from the excipients and degradation 
products, according to ICH requirements. The method 
is fast, selective, and requires a simple sample 
preparation procedure. Thus, the proposed LC method 
was successfully applied for the quantitative analysis of 
PB in tablet dosage forms and can be employed for 
drug analysis during stability studies, contributing to 
the improvement of quality control. 
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